Letter of Authorization and Consular Legalization for Jordan Registration
Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20
1. Key takeaways
The Letter of Authorization / Power of Attorney (LoA/PoA) is the only document in Jordanian registration that establishes the legal relationship between the overseas manufacturer and the local authorised representative. GRZAN’s conclusion is that an authorisation letter that has not been notarised and consularly legalised has no effect for establishing the record in the JFDA system.
- Second conclusion: an authorisation letter issued in China usually has to pass through the full four-stage process of notarisation → CCPIT certification → foreign affairs office certification → consular legalisation at the Jordanian embassy in China. In practice, consular legalisation of the FSC and the authorisation letter usually takes 4 to 6 weeks (practical estimate).
- Third conclusion: the authorisation letter is also the document that defines the boundaries of the AR’s powers. It does more than “authorise submission”; it also determines the AR’s delegated authority over vigilance reporting, variation filings, certificate renewal and import clearance, as well as the arrangements after termination.
2. Legal basis
The designation of the local authorised representative and the submission of the authorisation documents rest on the instruments listed below, each shown with its reference, publication date and the location of the relevant provisions.
| Title of regulation | Reference number | Publication date | Provision / location |
| Medical Devices (Including Sterilizers and Disinfectants) Importation Directives | Medical Devices Importation Directives Including Sterilizers & Detergents | Currently effective version | Provisions on designation of the local authorised representative and submission of authorisation documents |
| Criteria for the Circulation of Medical Devices, Sterilisers and Detergents | Criteria for the Circulation of Medical Devices, Sterilisers and Detergents | 2019 | Provisions on authorised representative obligations |
| Pharmacy and Drug Law | No. 12 | 2013 | General provisions on the regulation of health products |
Provision numbers are subject to the Arabic originals published in the Jordanian Official Gazette and issued by the JFDA; the 4-to-6-week figure is a practical estimate for the consular legalisation process.
3. Expert insights
The observations below reflect GRZAN’s review of authorisation letters and four-stage legalisation chains for Chinese manufacturers entering Jordan.
Insight 1: in Jordan the authorisation letter has a dual function — procedural and substantive. Procedurally, it is the indispensable document for the AR to open the record in the JFDA system; substantively, it defines the AR’s scope of representation and the allocation of responsibilities. When GRZAN reviews an authorisation letter, it examines the document from both angles at once. Checking both angles in one pass prevents a procedurally valid letter from creating substantively unbounded representation.
Insight 2: within the four-stage legalisation process, the embassy stage is the least controllable. The processing times of notarisation, the CCPIT and the foreign affairs office are relatively predictable, whereas the consular legalisation time at the Jordanian embassy in China is strongly influenced by the embassy’s working rhythm. Companies should treat the embassy stage as the priority buffer in their scheduling (practical estimate).
Insight 3: the validity period and termination clauses of the authorisation letter are the root of later disputes. Jordanian registration certificates are bound to the AR; if the authorisation letter expires or is terminated without any arrangement in place, the registration certificate will be left in an unstable state. GRZAN recommends that the authorisation letter expressly provide for: the validity period, the renewal mechanism, the triggers for termination, the handling of the registration certificate after termination, and the continuation of vigilance obligations. Written into the letter at the outset, these elements cost nothing to add and save months of negotiation later.
Insight 4: exclusive versus non-exclusive arrangements affect channel flexibility. Jordan’s licensed entities are highly fragmented, so when granting exclusivity companies should include performance-linked clauses to avoid channel stagnation after the grant.
Insight 5: the content of the authorisation letter must be consistent with the other documents. The manufacturer name and address, and the AR’s name and commercial registration number, must be fully identical to those in the FSC, the commercial registration certificate and the other documents. Name discrepancies are a common reason for rejection at formal review.
4. Practical recommendations
- First, advance the clause design of the authorisation letter and the legalisation process separately. Clause negotiation can run in parallel with the selection of the AR, and the legalisation process should start immediately once the clauses are settled. Keeping the two tracks separate prevents a legalisation delay from freezing negotiations that are still moving.
- Second, reserve 4 to 6 weeks for consular legalisation (practical estimate) and set the embassy stage as the priority buffer in the project plan. Shorter buffers routinely prove insufficient once embassy workload peaks.
- Third, specify in the authorisation letter the handling of the registration certificate after termination. This is the stage at which Chinese manufacturers are most easily left exposed in Jordan — without a contractual arrangement, the transfer of the registration certificate upon replacement of the AR can fall into deadlock.
- Fourth, set up an expiry alert for the authorisation letter. Before the letter expires, a renewal should be signed and legalised so that no “authorisation gap” arises.
5. Verification checklist
- □ The authorisation letter has completed the four-stage legalisation: notarisation → CCPIT → foreign affairs office → consular legalisation at the Jordanian embassy in China
- □ 4 to 6 weeks reserved for consular legalisation (practical estimate), with the embassy stage as the priority buffer
- □ The authorisation letter specifies the scope of representation: submission, vigilance, variations, renewal and import clearance
- □ The authorisation letter specifies the validity period, renewal mechanism and termination triggers
- □ The authorisation letter specifies the transfer or handling of the registration certificate after termination
- □ The manufacturer and AR information in the authorisation letter checked as consistent with the other documents
- □ An expiry alert mechanism for the authorisation letter is in place
- □ The cited provision numbers have been re-verified against the Arabic text of the Official Gazette
How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Jordanian market. Our team prepares JFDA-compliant dossiers, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com
Disclaimer
Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.
About GRZAN
GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.
GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.
Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.
What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.
Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.
Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.
Take your devices global with GRZAN
We work with manufacturers worldwide to open new markets with a clear regulatory pathway.
Contact us